What is Lexicon Pharmaceuticals's D&A?

Lexicon Pharmaceuticals (LXRX) reported D&A of $110K in Q1 2026.

How has Lexicon Pharmaceuticals's D&A changed year-over-year?

Lexicon Pharmaceuticals's D&A decreased by 37.5% year-over-year, from $176K to $110K.

What is the long-term trend for Lexicon Pharmaceuticals's D&A?

Over 4 years (2021 to 2025), Lexicon Pharmaceuticals's D&A has grown at a 20.8% compound annual growth rate (CAGR), from $292K to $621K.

Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.

Lexicon Pharmaceuticals LXRX D&A

D&A at other companies

PfizerPFE

$1.61B+33.2%

Vertex PharmaceuticalsVRTX

$55.9M+15.5%

Zevra Therapeutics, Inc.ZVRA

$316K-80.4%

MannkindMNKD

$4.37M+340%

Opko HealthOPK

$18.97M-4.5%

CytokineticsCYTK

——

Other financials

Income statement

See full

Revenue$21.1M+1,572%

Gross profit$21.0M+1,604%

Operating income-$996.0K+96.1%

Net income-$1.0M+95.9%

EPS (diluted)$0.00+100%

Balance sheet

See full

Cash & equivalents$67.1M+6.7%

Total debt$57.7M-45.7%

Total equity$202.9M+64.9%

Total assets$268.8M-9.7%

Cash flow

See full

Operating cash flow-$14.7M+66.4%

CapEx--100%

Free cash flow-$17.2M+21.5%

Valuation

See full

Market cap$986.12M+262%

Enterprise value$976.73M+209%

P/S14.2×+5.4×

Profitability

See full

Gross margin99.5%+1.5pp

Operating margin-34.8%-16.8pp

Net margin-37.5%-18.1pp

FCF margin-578.5%-283pp

Returns & leverage

See full

Return on equity-16%-7.2pp

Debt / equity0.3×-0.6×

Current ratio18.8×+16.6×

Where this comes from

Reported directly by Lexicon Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lexicon Pharmaceuticals's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Lexicon Pharmaceuticals's D&A?: Lexicon Pharmaceuticals (LXRX) reported D&A of $110K in Q1 2026.
How has Lexicon Pharmaceuticals's D&A changed year-over-year?: Lexicon Pharmaceuticals's D&A decreased by 37.5% year-over-year, from $176K to $110K.
What is the long-term trend for Lexicon Pharmaceuticals's D&A?: Over 4 years (2021 to 2025), Lexicon Pharmaceuticals's D&A has grown at a 20.8% compound annual growth rate (CAGR), from $292K to $621K.
What does D&A mean?: Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.